![](https://cdn.intelligentinsurer.com/convert/files/2024/06/7d0f2a30-2990-11ef-99bb-87d9d5fa7325-R%26Q_shutterstock_2156763317.jpg/r%5Bwidth%5D=320/7d0f2a30-2990-11ef-99bb-87d9d5fa7325-R%26Q_shutterstock_2156763317.webp)
R&Q in agony: shares trade down ca 82% on threat of liquidation
LSE-listed shares of specialty and legacy insurance group R&Q Holdings shed an immediate 72% on news of a possible liquidation, then slid further to flatline the remainder of the session with losses in excess of 80% as shareholders fled the scene.
Against the 12M high hit in September last year, shares are down in excess of 99%.
The mass exodus of shareholders followed word that R&Q was stumbling in its malingering attempts to shed its program management business in an attempt to raise cash for anxious creditors and, hopefully, walk away with its legacy business still intact.
But R&Q has struggled to close a sales deal with Onex that it originally penned back in October. Along the way, R&Q has its hands tied in legacy and has watched “significant” costs build up in its rescue efforts.
R&Q is now up against the wall. Onex has put forward an alternative deal structure that would see it pick up the asset only once R&Q is in liquidation. Remaining R&Q assets would also likely be sold off should that provisional liquidation begin, management surmised.
“In such circumstances there would be very little, if any, chance of any value accruing to the Company's shareholders,” R&Q management warned.
Management still talks of chances for the original deal.
“The Board is currently exploring and evaluating all options that may be available to the Company, including alternative transactions (including the Alternative Proposal) and potential sources of liquidity, whilst continuing to work to complete the original Sale,” management had said in its pre-session warning to markets.
Talks to sell R&Q's program management business to grease the rescue have dragged on. R&Q was forced to strike a stand-still deal with creditors in late April.
Did you get value from this story? Sign up to our free daily newsletters and get stories like this sent straight to your inbox.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Elliot Field at efield@newtonmedia.co.uk or Adrian Tapping at atapping@newtonmedia.co.uk